|
US7014998B2
(en)
|
2000-09-30 |
2006-03-21 |
Yale University |
Screening immunomodulatory agents by CTLA-4 upregulation
|
|
GB0103389D0
(en)
*
|
2001-02-12 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
|
US20050069538A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
|
WO2003048327A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Abgenix, Inc. |
Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
|
|
EP2075256A2
(en)
|
2002-01-14 |
2009-07-01 |
William Herman |
Multispecific binding molecules
|
|
WO2003061695A1
(en)
*
|
2002-01-17 |
2003-07-31 |
Amgen Inc. |
Methods of regulating cytokine receptor signaling
|
|
AU2003279657A1
(en)
*
|
2002-07-01 |
2004-01-19 |
Savient Pharmaceuticals, Inc. |
Compositions and methods for therapeutic treatment
|
|
AU2003263043A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Sangstat Medical Corporation |
Methods and compostions for immune tolerance
|
|
US20040047858A1
(en)
*
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
CA2535583A1
(en)
*
|
2003-08-25 |
2005-03-03 |
Pangenetics B.V. |
Method of inducing immune tolerance
|
|
KR20060079232A
(ko)
*
|
2003-09-18 |
2006-07-05 |
노파르티스 아게 |
치료용 결합 분자
|
|
WO2007092196A2
(en)
*
|
2006-01-27 |
2007-08-16 |
Cellerant Therapeutics, Inc. |
Compositions and methods for treating myeloid proliferative disorders
|
|
WO2007140457A2
(en)
*
|
2006-05-31 |
2007-12-06 |
Genzyme Corporation |
Methods of using anti-thymocyte globulin and related agents
|
|
EP2789625B1
(en)
|
2006-08-18 |
2018-06-06 |
Argos Therapeutics, Inc. |
Use of soluble CD83 for perfusing a tissue for transplantation
|
|
CN101594878A
(zh)
|
2006-09-18 |
2009-12-02 |
雷普特药品公司 |
通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
|
|
EP2127671B1
(en)
|
2007-02-07 |
2016-09-14 |
Nec Corporation |
Therapeutic agent for cancer
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
US9713636B2
(en)
|
2011-02-28 |
2017-07-25 |
Napajen Pharma, Inc. |
Nucleic acid/polysaccharide complex
|
|
EP2742944B1
(en)
*
|
2011-08-10 |
2018-06-27 |
Napajen Pharma, Inc. |
Immune tolerance inducer
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3174902B1
(en)
*
|
2014-08-01 |
2019-04-17 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
An anti-cd45rc antibody for use as drug
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601073D0
(en)
*
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
HK1258726A1
(zh)
|
2015-09-28 |
2019-11-15 |
Regents Of The University Of Minnesota |
嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
JP2019522050A
(ja)
|
2016-06-17 |
2019-08-08 |
マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
細胞の枯渇のための組成物および方法
|
|
US10111966B2
(en)
|
2016-06-17 |
2018-10-30 |
Magenta Therapeutics, Inc. |
Methods for the depletion of CD117+ cells
|
|
US20190315878A1
(en)
|
2016-11-07 |
2019-10-17 |
Argos Therapeutics Inc. |
Bispecific antibodies that modulate tlr-4 signaling and uses thereof
|
|
US10576161B2
(en)
|
2017-01-20 |
2020-03-03 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of CD137+ cells
|
|
EP3514541A1
(de)
*
|
2018-01-17 |
2019-07-24 |
Siemens Healthcare Diagnostics Products GmbH |
Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
|
|
CA3128518A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Actinium Pharmaceuticals, Inc. |
Molecules and their derivatives directed against cd45
|
|
CN111707833A
(zh)
*
|
2020-06-19 |
2020-09-25 |
徐州医科大学 |
小鼠血管内外淋巴细胞识别的方法及其应用
|
|
JP2024500189A
(ja)
|
2020-12-21 |
2024-01-04 |
アロジーン セラピューティクス，インコーポレイテッド |
プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
CN116997654A
(zh)
|
2021-03-17 |
2023-11-03 |
第一三共株式会社 |
编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
US20230399375A1
(en)
|
2022-04-15 |
2023-12-14 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
WO2023240064A1
(en)
|
2022-06-08 |
2023-12-14 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
CN120554513B
(zh)
*
|
2025-07-28 |
2025-11-21 |
杭州华大生命科学研究院 |
一种抗cd45抗体及其应用
|